eligibility_summary
Eligible: signed informed consent, previously treated with Relma‑cel (including off‑label), if enrolled in another study, must have completed follow‑up or been withdrawn/lost to follow‑up. Excluded: patients treated with Relma‑cel who subsequently received other CAR‑T products.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT06142188. Intervention: Relmacabtagene autoleucel (relma‑cel, JWCAR029), a biological autologous chimeric antigen receptor T‑cell (CAR‑T) therapy. Mechanism: patient T cells are engineered to express an anti‑CD19 CAR, upon binding CD19 on malignant B cells, CAR signaling (CD3ζ with costimulation) activates T‑cell cytotoxicity and cytokine release, driving targeted lysis of CD19+ cells and B‑cell aplasia. Targets: CD19 on B‑cell malignancies (large B‑cell lymphoma, follicular lymphoma), pathways/cells affected include CAR‑mediated T‑cell activation, cytotoxic effector pathways, and depletion of CD19+ B cells. Design: observational, real‑world, long‑term follow‑up (up to 15 years) of adults in China treated with relma‑cel, typical single IV dose ~1×10^8 CAR‑T cells.